Data on the consequences of cirrhosis regression on portal hypertension and on splanchnic and systemic hemodynamic are scarce. Previous studies have reported a decrease in hepatic venous pressure gradient following antiviral treatment in patients with hepatitis B or C related cirrhosis. However, these studies did not investigate splanchnic and systemic hemodynamic changes associated with virus control. To fill this gap in knowledge, in a recent issue of Clinical Science, Hsu et al. (vol. 132, issue 6, 669-683) used rat models of cirrhosis induced by thioacetamide and by bile duct ligation and provided a comprehensive analysis of the effects of cirrhosis regression on splanchnic and systemic hemodynamics. They observed a significant reduction in portal pressure accompanied by a normalization of systemic hemodynamic (normal cardiac index and systemic vascular resistance) and a decrease in intrahepatic vascular resistance. No change in extrahepatic vascular structures were observed despite normalization of collateral shunting, meaning that portosystemic collaterals persist but are not perfused. One intriguing part of their results is the only marginal effect of cirrhosis regression on liver hyperarterialisation. This result suggests that changes in splanchnic hemodynamic features induced by cirrhosis remain when hepatic vascular resistance decreases, raising the hypothesis of an autonomous mechanism persisting despite regression of intrahepatic vascular resistance. Microbiota changes and bacterial translocation might account for this effect. In conclusion cirrhosis regression normalizes systemic hemodynamics, but some splanchnic hemodynamic changes persist including extrahepatic angiogenesis and liver hyperarterialization.
Skip Nav Destination
Article navigation
June 2018
-
Cover Image
Cover Image
Double immunofluorescence staining for mindin (red) and CD68 (green) in atherosclerotic plaques of HFD-treated APOE-/- mice. In Issue 11 of Clinical Science, Zhu et al. discuss mindin deficiency as a novel mediator in protecting against foam cell formation and atherosclerosis, through direct interaction with LXR-β; for details, see pages 1199–1213.
Commentary|
June 28 2018
Cirrhosis regression: extrahepatic angiogenesis and liver hyperarterialization persist
Audrey Payancé;
Audrey Payancé
1DHU Unity, Pôle des Maladies de l’Appareil Digestif, Service d’Hépatologie, Centre de Référence des Maladies Vasculaires du Foie, Hôpital Beaujon, AP-HP, Clichy, France
2Université Denis Diderot-Paris 7, Sorbonne Paris Cité, 75018 Paris, France
Search for other works by this author on:
Pierre-Emmanuel Rautou
1DHU Unity, Pôle des Maladies de l’Appareil Digestif, Service d’Hépatologie, Centre de Référence des Maladies Vasculaires du Foie, Hôpital Beaujon, AP-HP, Clichy, France
2Université Denis Diderot-Paris 7, Sorbonne Paris Cité, 75018 Paris, France
3Inserm, U970, Paris Cardiovascular Research Center - PARCC, 56 rue Leblanc 75015 Paris, France
Correspondence: Pierre-Emmanuel Rautou ([email protected])
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
April 23 2018
Revision Received:
May 19 2018
Accepted:
May 22 2018
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© 2018 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society
2018
Clin Sci (Lond) (2018) 132 (12): 1341–1343.
Article history
Received:
April 23 2018
Revision Received:
May 19 2018
Accepted:
May 22 2018
Connected Content
Citation
Audrey Payancé, Pierre-Emmanuel Rautou; Cirrhosis regression: extrahepatic angiogenesis and liver hyperarterialization persist. Clin Sci (Lond) 29 June 2018; 132 (12): 1341–1343. doi: https://doi.org/10.1042/CS20180129
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Cited By
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |